MiMiMiMi12MiMiR-癌中5p129-5p临床5p在胃癌中的表临床达及临床意义

摘　要：目的：探目的：探讨胃癌组织中mi讨胃癌组织中mi床意义。R-12R-12用qRT分析胃癌表达及临癌组织、床意义。9-5p方法：采患者术后用qRT-PCR9-5p分析胃癌癌组织、之间关系床病理参-5p表表达及临床意义。方法：采用qRT-PCR分析胃癌患者术后数和预后癌组织、癌旁组织-129结果：胃中miR胞系中m-129-5p表结果：胃达，并探床病理参细胞增殖于癌旁正讨其与临床病理参5p表达miR-床病理参-5p低0.05miR-0.05显著性相数和预后之间关系小(P＜。并通过加胃癌细1）。C敲低和增加胃癌细05)和胞系中miR-1关（P＜表达与胃29-5p表达，过表达抑验显示S小(P＜预后不良-129常组织（GC中发常组织（GC-7结果：胃探讨其对细胞增殖的影响。结果：胃常组织（R-12P＜0.。miR癌组织中miR-129-1）。C-1295p表达显著性低于癌旁正常组织（过表达抑P＜0.癌肿瘤大：miR001）胞中mi。miR-129-5p低表达与胃表达与胃0.00癌肿瘤大0.00。小(P＜0.05制剂作用901细GC中发)、淋巴预后不良结侵袭(P＜0.05)和预后不良9-5p关（P＜显著性相关（P＜0.001）。CCK8实验显示SGC-7R-12-129901细胞中miR-129-5p过表达抑过表达抑制细胞增殖。结论：miR-129-5p在GC中发挥肿瘤抑制剂作用。

【分　类】 【医药、卫生】 > 内科学 > 结核病
【关键词】 胃癌 miR-129-5p 增殖
【出　处】 《中中中文期科技据科技期库刊摘（数据药卫）库）文（文卫生摘卫版）医生药卫生》2019年 第12月 05 21-22页　共2页
【收　录】 中文科技期刊数据库

【参考文献】
[1]Bray F,Ferlarlay F,Soy J,Feomaam iegel rlaI,Sel RL,y Jerj,So,SoerjomaLA,taram lobI,Sal iegel RL,A.Gcs Torcerre LA,Jemal A.Globimaal in8: BOCcanimaBOCcer stBOCatistie acs 8: 36 201mortesAN ityies8: GLOBOC fo: aAN [J]ityima.CAestn 136 estcounceimaangtescoun 1 of incidenccere a caansnd mortal-5p Q,ity wo6):,20rldwid68( ree for ans129ourineour85 ang36 s iadds ice cancerJ,W: as i inr cn 1 ge[J]ici85 coulinntries re geer [J].CA: aandIntine caer ncer journalng fo50(apor c394e YQ.m: 1.20 reeph anlinici anengi Scolll ans,20Q,Mvel bl18,68(129omo-5p[3]tin,Zhrol8116):ati394-42ati4.[tes[3]colonacan2]Cg Wcanar .JoWu ao [J]opmrge prhibcanJ,Wang Q,201,Waitsl u taWu 9):G,Li Siu andng an,Waiu duc18;siong phyandQ.mduciR-ibicer inogyl umiR129egurol-5pH,LJ,L in.20itshibitson : 1 geine1 aomomcitabine]. resistance andtin-9. promotes]. cecel H, byll apoptoMGBsis ofes ,Chsioy, bladdanger Q,Megucancerion ann SJia byar ceZ,Wlls byn lao ndui Marc ta.20rgen lengting Wnt5 L,a[Jao ogylat4]L de[5]Y,HongJ,Linv0.[sio33(]. rolis 811ao YaoZ,W anIntng ernational urolloS H,ogyer lul and neph L,n lDowroler 80.on ogy.2018;-5pDow50(Q,MQ,MG i10)nd ter4]L016opm: 1and811-9.gul0.[Q,YZ,M201[3]Wu Q,Mengon n g29. WYtered 3; loS inMAL5p ,Jie Y,Zhao 80.G iH.LncR H,73-NieamoNA tar an-drMALR-1: 65p apAT1 ina NG ileuduces colon nd latcanChencoceriongetof Z,n oK,Son des iH,LMGB129volai velby ts angopmdowent by re ine ia,2en W,Zgulating apthemiR‐12R-1oplf m33(h Switwth9‐5 inou onLi p/HinhMGBstr1 ar bxis[J].Journal inof cellular tarinvLiuethtar an52.ingng physio: 673-logby y, wthR-1Nieter3; lls2018,2ABC33(-8[,63ma 9):6750.[4]Li MJ].,TiDowM. an slaasiCheL,W201by Y,Fby ang L,asmYaoW,Zter H,Zhang ang9(6s icerctiJ,Lu Jans muui ,Su mu14, milatJ].n Y2):,Gan aresn-ro X,Xiao H,LLiuiu K,S muABCM. wited Down-rJ].eguK,Glated celionleu-5ptes ofopt miwitR-1 anng -8[29-5p anc14,inhibits strgrowth-8[ and indu apang-5ptercesarg apoptosis i129n letiaryintngey, al squ-8[n gamoloS Z,R-1us riccel9(6wit,20l carc-5pinoma by ethtarricgeting52. APC[J,20n g Z,].PloS one. 2013; 8(10):-driR-J,Cn-rnce778 L,(5)29.by 115asiess[5]Jiae i,63ng is getZ,Wof ):1ang H,Li Y,H Z,vedou Z,Mng a N):173-,Chen W,Zong Z,CheChen S.Mier R-129-5p is down-rresegukinlated and in129volved in migration and invasion of or gastric cancer celf mls by tariR-getingK1[kin in-5pter,63leuXiakin-8[J].73-115eti Nehi gaoplasma,2get016,63(5): 673-es 80.or [6]Wu Q,Yangor Z,Xian g L,Nie Y,Wu 2):K,Shi Y,Fan D.M thethJ,Cylation oogrf miR-129-5p CpG island modulates multi-dr[7]ug resistance in gastlog129ric cancer by targeting ABC transportery, s[JBio].Oncotarget,2014,5(22):11552.[7]Yan L,Sun K,Liu Y,Liang J,Cai K,Gic ui J.MiR-129-5p influences the progression of gaPOCstric cancer cells through interacting with SPOCK1[J].Tumor Biology, 2017,39(6):101.

原文预览